Preventing and curing multiple sclerosis by controlling Epstein–Barr virus infection

Pender, Michael P. (2009) Preventing and curing multiple sclerosis by controlling Epstein–Barr virus infection. Autoimmunity reviews, 8 7: 563-568. doi:10.1016/j.autrev.2009.01.017


Author Pender, Michael P.
Title Preventing and curing multiple sclerosis by controlling Epstein–Barr virus infection
Journal name Autoimmunity reviews   Check publisher's open access policy
ISSN 1568-9972
1873-0183
Publication date 2009-06
Sub-type Article (original research)
DOI 10.1016/j.autrev.2009.01.017
Volume 8
Issue 7
Start page 563
End page 568
Total pages 6
Place of publication Philadelphia, PA, United States
Publisher Elsevier
Language eng
Abstract It has been noted since 1981 that late primary infection with the Epstein–Barr virus (EBV) in adolescence or young adulthood can account for the epidemiology of multiple sclerosis (MS), including the association with higher socio-economic status, the latitudinal variation in prevalence, the effects of migration on the risk of acquiring MS, and the occurrence of clusters and epidemics. Virtually all (> 99%) people with MS are EBV seropositive, suggesting that EBV infection is essential for the development of MS. The EBV-infected autoreactive B-cell hypothesis of autoimmunity published in 2003 proposes that, in genetically susceptible individuals, EBV-infected autoreactive B cells seed the target organ where they produce pathogenic autoantibodies and provide costimulatory survival signals to autoreactive T cells. This hypothesis makes several predictions, some of which have been verified in the case of MS, namely: the presence of EBV-infected B cells in the central nervous system; a beneficial response to B-cell depletion with rituximab; and decreased CD8+ T-cell immunity to EBV-infected B cells. The hypothesis also predicts that chronic autoimmune diseases will respond to treatment which controls EBV infection. Thus it is proposed that vaccination against EBV will prevent MS, and that effective antiviral drugs will inhibit disease progression in people with MS and potentially be curative.
Keyword Epstein-Barr virus
Multiple sclerosis
Therapy
Antiviral drugs
Q-Index Code C1
Q-Index Status Provisional Code
Institutional Status UQ

Document type: Journal Article
Sub-type: Article (original research)
Collection: School of Medicine Publications
 
Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 40 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 43 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Created: Thu, 12 Aug 2010, 20:37:55 EST by Ms Marianne Sato on behalf of School of Medicine